ALK Reports Outstanding Results for 2024 Financial Year
ALK’s Board of Directors has proudly announced the annual report for 2024, showcasing what has been recognized as a historic performance for the company. This year marked a significant milestone as ALK (ALKB:DC / OMX: ALK B / AKBLF) achieved a 15% sales growth and a remarkable 65% increase in profits. Analysts and stakeholders are optimistic as the company looks to maintain its growth trajectory in the upcoming years.
Highlights from Q4 2024
The fourth quarter of 2024 has been impressive, with revenue climbing 11% to DKK 1,499 million. This growth is largely attributed to ALK's strong performance in Europe, even though North America and other international markets remained flat for this quarter.
Key Figures from Q4
- Tablet sales surged by 17% to reach DKK 795 million, with Europe as the standout region, indicating a robust demand for allergy treatments.
- Combined sales of SCIT and SLIT-drops were up by 5%, indicating steady growth in this sector.
- Operating profit increased moderately to DKK 205 million, reflecting investments in both research and development and marketing initiatives.
- ALK made significant strides, including the in-licensing of the neffy adrenaline nasal spray and achieving pediatric approval for the ACARIZAX house dust mite tablet in Europe.
Full-Year Results for 2024
Looking at the complete fiscal year of 2024, ALK reported a total revenue increase of 15%, hitting DKK 5,537 million across all product lines. This demonstrates the company’s successful expansion and refinement of its offerings.
Annual Performance Breakdown
- Tablet sales alone soared by 24%, indicating a thriving market demand.
- Sales of SCIT and SLIT-drops rose by 6%, reaffirming the effectiveness of ALK’s allergy treatment methods.
- EBIT reached DKK 1,091 million, showcasing a significant profit margin improvement.
- Despite challenges, free cash flow saw an unexpected rise when discounting one-off payments, ending at DKK 790 million.
Looking Towards 2025
As ALK prepares for an exciting 2025, the company anticipates revenue growth of between 9% and 13%. This forecast is driven primarily by volume increases across diverse sales regions and product lines, particularly in tablets.
Financial Outlook
- The EBIT margin is expected to hit around 25%, benefiting from ongoing improvements in gross margins and strategic optimizations.
Insights from CEO Peter Halling
ALK’s CEO stated that 2024 was a remarkable year, exceeding initial expectations significantly. With a robust strategic framework in place, ALK is expanding its addressable markets, especially targeting children and diversifying into areas of significant unmet medical needs, such as food allergies and anaphylaxis.
Contact Information
ALK-Abelló A/S
For further inquiries, please reach out to:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
Frequently Asked Questions
What was ALK's sales growth rate in 2024?
ALK achieved a sales growth rate of 15% for the year 2024.
How much did ALK's profits increase in 2024?
The company's profits increased by an impressive 65% in 2024.
What are the expectations for 2025?
In 2025, ALK expects revenue growth of 9% to 13%, primarily from volume increases.
What significant milestones did ALK achieve in 2024?
ALK in-licensed the neffy adrenaline nasal spray and received pediatric approval for ACARIZAX.
Who can be contacted for more information about ALK?
For more information, you can reach out to Per Plotnikof for investor inquiries or Maiken Riise Andersen for media questions.
